Medinice S.A (ICE.WA) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · Poland · ISIN PLMDNCE00016

Price
55.30 PLN
Market cap
577.98 m PLN
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-7.63 %
Return on assets (ROA)
-7.25 %

Medinice S.A financials

Fiscal year20242025
Revenue188,000.00 PLN0.00 PLN
Gross profit-26,000.00 PLN-166,000.00 PLN
Operating income37.23 m PLN-6.78 m PLN
EBIT37.60 m PLN-6.70 m PLN
Net income37.58 m PLN-6.72 m PLN
Diluted EPS – continuing operations5.62 PLN-0.80 PLN

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Medinice S.A

Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium; and AtriClamp, a clip designed to close the left atrial appendage to minimize the risk of stroke in patients with atrial fibrillation. It also provides MiniMax, an ablation-mapping catheter used for detecting intracardiac electrophysiological signals, creating a 3D map of the heart, and performing intracardiac irrigated RF ablation to treat arrhythmias caused by abnormalities in the heart's conduction system; and EP Bioptom, an electrode for endomyocardial biopsy using 3D mapping enabling simultaneous biopsy and creation of a three-dimensional heart map. The company was founded in 2012 and is headquartered in Warsaw, Poland.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.